Distinguishing product and practice regulation in personalized medicine

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 2, 2007, Pages 288-293

  Evans, B J ^a  

^a Indiana University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TRASTUZUMAB;

DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; LAW; MEDICAL PROFESSION; MEDICARE; OFF LABEL DRUG USE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; VALIDATION STUDY;

DELIVERY OF HEALTH CARE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL AUTONOMY; PUBLIC POLICY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33846635128     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100042     Document Type: Review

References (43)

1. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938), as amended (codified at 21 U.S.C. §§301-399).
2. Hoffmann, J.E. Administrative procedures of the Food and Drug Administration. In Fundamentals of Law and Regulation: An In-depth Look at Therapeutic Products, Vol. II (eds. Adams, D.G., Cooper, R.M. & Kahan, J.S.) 17-24 (Food & Drug Law Institute, Washington, DC, 1999).
3. Department of Health, Education, and Welfare (HEW). FDA, legal status of approved labeling for prescription drugs; prescribing for uses unapproved by the Food and Drug Administration (Notice of Proposed Rulemaking), 37 Fed. Reg. 16,503-05, (July 30, 1972).
4. Adams, D.G. The Food and Drug Administration's Regulation of Health Care Professionals. In Fundamentals of Law and Regulation, supra note 2, 423.
5. HEW, supra note 3, at 16503-04.
6. Department of Health & Human Servs., FDA, Draft Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays (Docket No. 2006D-0347) (September 5, 2006), available at www.fda.gov/OHRMS/DOCKETS/98fr/ch0641.pdf.
7. Joint National Institutes of Health - Department of Energy Ethical, Legal and Social Implications Working Group of the Human Genome Project, Task Force on Genetic Testing. Promoting Safe and Effective Genetic Testing in the United States (eds. Holtzman, N.A. & Watson, M.S.), Ch. 2 (September 1997), at http://www.genome.gov/10002404.
8. National Institutes of Health, Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT (July, 2000), at http://www4.od.nih.gov/ oba/sacgt/gtdocuments.html see Executive Summary at x.
9. Department of Health & Human Servs., Establishment of the Secretary's Advisory Committee on Genetics, Health, and Society, 67 Fed. Reg. 65126 (October 23, 2002).
10. UK Human Genetics Commission. Genes Direct: Ensuring the Effective Oversight of Genetic Tests Supplied Directly to the Public (March, 2003), at http://www.hgc.gov.uk/client/Content.asp?ContentID=266.
11. Hogarth, S., Melzer, D. & Zimmern, R. The Regulation of Commercial Genetic Testing Services in the UK: A Briefing for the Human Genetics Commission (2005), at http://www.hgc.gov.uk/Client/ document.asp?DocId= 97&CategoryId=8.
12. World Health Organization. Quality & Safety in Genetic Testing: An Emerging Concern, at http://www.who.int/genomics/policy/en/.
13. OECD. Genetic Testing: Policy Issues for the New Millennium (2001), at http://www.oecd.org/document/16/0,2340,en_2649_37407_ 1895632_1_1_1_37407,00.html.
14. OECD. Quality Assurance and Proficiency Testing for Molecular Genetic Testing: Survey of 18 OECD Member Countries (2005), at http:// www.oecd.org/dataoecd/25/12/34779945.pdf.
15. Collins, F.S., Green, E.D., Guttmacher, A.E. & Guyer, M.S. A vision for the future of genomics research. Nature 422, 835-847, at 840-42 (2003).
16. Feigal, D.W. 'Future Trends' (July 18, 2000) (presented before the AdvaMed Submissions Workshop, Washington DC), available at: http://www.fda.gov/ cdrh/present/hima-7-19-00-feigal.pdf. See slides 21-23.
17. National Academy of Sciences, National Cancer Policy Board. Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis, 225 (2005), at http://www.nap.edu/catalog/11016.html.
18. Enterprise Analysis Corporation. Molecular diagnostics - An In-Depth Survey of the US Molecular Diagnostic Laboratories (November 2003), at http://www.researchandmarkets.com/reports/310296.
19. Evans, B.J. What will it take to reap the clinical benefits of pharmacogenetics? Food Drug Law J. 61, 753-794 (2006).
20. Pub.L. 100-578, October 31, 1988, 102 Stat. 2903, codified at 42 U.S.C. §263a et seq.; 42 C.F.R. Pt. 493.
21. Gutman, S. Clinical Chemistry Forum: the role of Food and Drug Administration regulation of in vitro diagnostic devices - applications to genetics. Clin. Chem. 45, 746 (1999).
22. Department of Health & Human Servs., FDA, Final Rule, Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific Reagents, 62 Fed. Reg. 62243-49 (1997).
23. Schifreen, R.D. & Louth, C. Industry view on the regulation of ancillary reagents. Food Drug Law J. 51, 159 (1996).
24. FDA. FDA Drafts Regulatory Guidance to Industry and Labs for Group of Medical Tests. FDA News P06-127 (September 5, 2006), at http:// www.fda.gov/bbs/topics/NEWS/2006/NEW01445.html.
25. Pollack, A. F.D.A seeks to regulate new types of diagnostic tests, The New York Times, n.p. (September 6, 2006).
26. SACGT, supra note 8, at x, 15-20.
27. Evans, B.J. & Flockhart, D.A. The unfinished business of U.S. drug safety regulation. The Food Drug Law J. 61, 45-63 (2006).
28. HEW, supra note 3, at 16503-04.
29. Id. at 16504.
30. Evans, supra note 19, at 783-85.
31. Letter from Yocher, R., Genzyme Corp., filed with FDA (July 15, 2005), p 1.
32. Letter from Hall, S.T., GlaxoSmithKline, filed with FDA (June 30, 2005), see Comments §6, p 4.
33. Letter from Jones, C.D., Advanced Medical Technology Association (AdvaMed), filed with FDA (July 15, 2005), p 2.
34. See, e.g., approved package insert for trastuzumab (Herceptin™), at http://www.gene.com/gene/products/information/oncology/ herceptin/ insert.jsp see sections entitled "CLINICAL STUDIES: HER2 Detection"and "PRECAUTIONS: HER2 Testing," which cross-reference package inserts for the HercepTest™ IHC assay and the Pathvysion™ HER-2 DNA Probe Kit (FISH test) products.
35. See, e.g., approved package insert for Atomoxetine HCl (Strattera™); see sections entitled "Human Pharmacokinetics: Metabolism and elimination," "Drug-Drug Interactions," and "PRECAUTIONS: Drug-Drug Interactions," noting that the drug is metabolized primarily through the CYP2D6 enzymatic pathway and commenting on the possible need for dosage adjustment when the drug is co-administered with certain CYP2D6 inhibitors.
36. Lesko, L.J. & Woodcock, J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. 3, 763-769 (2004).
37. See, e.g., FDA, New Device Clearance: Roche Amplichip Cytochrome P450 Genotyping tests and Affymetrix GeneChip Microarray Instrumentation System - K042259, at http://www.fda.gov/cdrh/mda/ docs/k042259.html.
38. FDA/DIA Workshop: Combination Products and Mutually Conforming Labeling (May 10, 2005), http://www.fda.gov/oc/combination/ presentations/dia/dia05_10.html. See, Presentation of Nancy Stade, Office of the Chief Counsel, FDA, Legal Considerations in Cross Labeling Policy; Presentation of Suzanne O'Shea, Office of Combination Products, FDA, Perspectives on Cross Labeling.
39. Id., Presentation of Anna Longwell, Roche Diagnostics, FDA's Role in Encouraging Innovation in Combination Products; Presentation of David Eveleth, Pfizer, Inc., Combination Products and Mutually Conforming Labeling.
40. FDA, Classification regulation for drug metabolizing enzyme genotyping system, 21 C.F.R. §862.3360.
41. FDA, Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Drug Metabolizing Enzyme Genotyping System (March 10, 2005), at 12.
42. Id. at 13.
43. American Medical Association. CPT process - how a code becomes a code, at http://www.ama-assn.org/ama/pub/category/print/3882.html.